859027-00-2Relevant academic research and scientific papers
THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS
-
, (2013/04/10)
The invention relates to compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of cancer.
FLUORO-SUBSTITUTED COMPOUNDS AS KINASE INHIBITORS AND METHODS OF USE THEREOF
-
, (2011/02/24)
The present invention provides for novel compounds of Formula I and pharmaceutically acceptable salts and solvates thereof which have kinase inhibitor activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating and preventing a Bcr-Abl, c-Kit or PDGF-R mediated disorder for which one or more kinase inhibitor is indicated, including neoplasia such as chronic myelogenous leukemia or gastrointestinal stromal tumors. The present invention also provides for processes of making the compounds of Formula I, including salts and solvates thereof, and pharmaceutical compositions comprising the same.
Synthesis, crystal structure, and spectral characterization of flumatinib mesylate
Xu, Gang,Shen, Hong,Tong, Taifeng,Lu, Aifeng,Gou, Shaohua
scheme or table, p. 2564 - 2570 (2010/09/30)
Flumatinib mesylate, a 3-substituted picolinamide derivative structurally similar to imatinib mesylate, was prepared. The compound was characterized by infrared, ultraviolet, NMR, and electrospray ionization-mass spectra together with X-ray crystal struct
AMIDE DERIVATIVE AND MEDICINE
-
Page/Page column 23, (2010/11/23)
The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula [1]: (wherein R1 represents -CH2-R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.
Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors
Asaki, Tetsuo,Sugiyama, Yukiteru,Hamamoto, Taisuke,Higashioka, Masaya,Umehara, Masato,Naito, Haruna,Niwa, Tomoko
, p. 1421 - 1425 (2007/10/03)
A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bc
PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS
-
Page/Page column 158-159, (2008/06/13)
The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.
